G-CSF (Granulocyte Colony Stimulating Factors) Market Analysis, Trends, Growth, Research And Forecast 2032

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company's G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023 identifies increasing demand for prophylaxis granulocyte colony-stimulating factor as the major driver for the G-CSF market's growth in the forecast period. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the G-CSF market.

The global G-CSF market reached a value of nearly $5,005.6 million in 2020, having decreased at a compound annual growth rate (CAGR) of -5.3% since 2015, primarily due to high uptake of biosimilars in the EU and USA and COVID impact. The market is expected to grow from $5,005.6 million in 2020 to $5,721.6 million in 2025 at a rate of 2.7%. The global granulocyte colony stimulating factors market is then expected to grow at a CAGR of 6.3% from 2025 and reach $7,761.1 million in 2030.

Download Free Sample Of G-CSF (Granulocyte Colony Stimulating Factors) Market Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3930&type=smp

Major competitors in the G-CSF market are Amgen Inc., Coherus Biosciences Inc., Sandoz (Novartis), Biocon/Mylan, Teva Pharmaceutcals Inc.

A key trend in the G-CSF market includes increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF).The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the G-CSF market.

Read More On The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report Here:
https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

The G-CSF market is segmented -
By Type -
The G-CSF (Granulocyte Colony Stimulating Factors) market is segmented by type
• a) Pegfilgrastim
• b) Filgrastim
• c) Lenograstim
• d) Others

By Application-
The Granulocyte Colony Stimulating Factors market is segmented by application
• a) Oncology
• b) Blood Disorders
• c) Chronic and Autoimmune Disorders
• d) Others

North America was the largest region in the G-CSF market.

The Business Research Company's "Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The G-CSF (Granulocyte Colony Stimulating Factors) Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3930

The Table Of Content For The G-CSF (Granulocyte Colony Stimulating Factors) Market Include:
1. G-CSF (Granulocyte Colony Stimulating Factors) Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
……
21. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market
22. G-CSF (Granulocyte Colony Stimulating Factors) Market Opportunities And Strategies
23. G-CSF (Granulocyte Colony Stimulating Factors) Market, Conclusions And Recommendations
24. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.